In this study, multiple myeloma participants with secondary immunodeficiency (SID) will be treated with HyQvia according to their clinic's standard practice. The study's main aim is to look into infusion parameters of HyQvia administration.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Ability and willingness to provide informed consent. For adult participants unable to provide informed consent, informed consent provided by the legally authorized representative (LAR).
✓. Has a diagnosis of MM requiring systemic anti-myeloma therapy as per International Myeloma Working Group (IMWG) criteria.
✓. Initiated HyQvia treatment as part of routine clinical care no more than 30 days before study enrollment or received no more than 2 doses of HyQvia treatment, whichever occurs first. Participants are also eligible if they newly start HyQvia within 30 days after the enrollment visit.
✓. Age \>=18 years old at the time of MM diagnosis.
✓. Available medical history records starting from the diagnosis of MM requiring systemic anti-myeloma therapy as IMWG criteria.
✓. Life expectancy \>6 months at the time of enrollment, per physician assessment.
✓. Eastern Cooperative Oncology Group (ECOG) performance status score of \<=2.
✓. Participants/LAR willing and able to comply with the requirements of the protocol.
Exclusion criteria
✕. Known hypersensitivity to any of the components of HyQvia.
✕. Primary immunodeficiency (PID) or diagnosed with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) and/or active hepatitis C and/or active hepatitis B infection.
. Prior use of Ig treatment or prophylaxis within 3 months from the date of enrollment.
✕. Serious infection(s) requiring intravenous (IV) treatment at the time of enrollment into the study; except for participants on short-term oral antibiotic therapy.
✕. Has participated in an interventional clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in an interventional clinical study involving a medical product or device during this study.
✕. Planned stem cell transplant during the treatment period or had a prior stem cell transplant: allogeneic transplant at any time, autologous transplant within 3 months of enrollment.
✕. History of malignancy (other than MM) within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, localized prostate cancer or other non-invasive lesion that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 3 years).
✕. Participant has had major surgery within 2 weeks before enrollment, or has not fully recovered from an earlier surgery, or has surgery planned during the time the participant is expected to participate in the study.
10
Number of Participants Characterized by Site of Care
Timeframe: Up to 12 months
11
Length and Diameter of Infusion Needles
Timeframe: Up to 12 months
12
Number of Participants per Type of Pump
Timeframe: Up to 12 months
13
Number of Participants With Availability of Caregiver Support
Timeframe: Up to 12 months
14
Number of Training Visits
Timeframe: Up to 12 months
15
Number of Participants With Infusions That are Discontinued, Slowed, or Interrupted
Timeframe: Up to 12 months
16
Number of Participants With Reasons of infusions Discontinued, Slowed, or Interrupted
Timeframe: Up to 12 months
17
Number of Participants With Reasons for Discontinued, or Interrupted HyQvia Treatment or Switches to Other Treatment